We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Pneumatic Compression Reduces Lymphedema Consequences

By HospiMedica International staff writers
Posted on 15 Oct 2015
Lymphedema patients saw a nearly 80% reduction in their cellulitis episodes by using an advanced pneumatic compression device (APCD) at home, according to a new study.

Researchers at Vanderbilt University (Nashville, TN, USA) and the University of Minnesota (UMN; Minneapolis, USA) conducted a retrospective analysis involving 718 patients (both with and without cancer) to examine the impact of an APCD on cutaneous and other clinical outcomes, as well as health economic costs. The researchers compared outcomes for the year before and after APCD purchase, with the main outcomes and measures including rates of cellulitis, use of lymphedema-related manual therapy, and outpatient and inpatient hospitalizations.

Image: The Flexitouch APCD System during use (Photo courtesy of Tactile Medical).
Image: The Flexitouch APCD System during use (Photo courtesy of Tactile Medical).

The results showed that APCD use was associated with reduction in cellulitis episodes, lymphedema-related manual therapy, and outpatient visits. Among the cancer cohort, total lymphedema-related costs per patient were reduced by 37% (from USD 2,597 to USD 1,642). Reductions in physical therapy and outpatient visits resulted in a 37% decrease in lymphedema-related costs per patient, excluding medical equipment, among those with cancer, and a 36% decrease in costs for the non-cancer cohort. The study was published on October 7, 2015, in JAMA Dermatology.

“This could be a game-changer in the area of lymphedema care. Up to 10 million people in the United States are living and oftentimes suffering with symptoms of lymphedema,” said study co-lead author Prof. Sheila Ridner, PhD, of Vanderbilt University School of Nursing. “The idea that a home advanced pneumatic compression device can provide relief, decrease the number of cellulitis episodes, and save money is an important new option for patients.”

“Patients with lymphedema turn to dermatologists, primary care, and vascular physicians for treatment, and now these providers have a therapy to improve skin, limb, and systemic health for these individuals,” said Jerry Mattys, CEO of Tactile Medical (Minneapolis, MN, USA), which developed the Flexitouch APCD system used in the study. “This device sequentially inflates over areas of the body affected by lymphedema to facilitate the movement of excess fluid from the limb back to the cardiovascular system.”

Lymphedema is an accumulation of fluid in tissues commonly caused by abnormalities in the lymphatic system or removal or damage to a person's lymph nodes. Symptoms include swelling, recurrent cellulitis, loss of physical function, psychological stress and diminished quality of life. Lymphedema cannot be cured and is typically managed through combined therapies of manual lymph drainage, multilayer bandaging, decongestive exercise, skin care, and long-term self-management.

Related Links:

Vanderbilt University
University of Minnesota
Tactile Medical



Gold Member
12-Channel ECG
CM1200B
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Bronchoscopy Head Support
Reison 10-330

Latest Critical Care News

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs

On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants